Composition and method for treatment of psoriasis
AssigneesPanda Pharmaceuticals, L.L.C., The University of Tennessee Research Corporation
InventorsE. William Rosenberg, Thomas M. Glenn, Robert B. Skinner, Jr., Patricia W. Noah
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions and methods for use in the treatment of psoriasis, having isopropyl myristate as a first active ingredient and a different anti-psoriatic agent as a second active ingredient; preferably they are combined in the same pharmaceutical composition.
Claims36
A pharmaceutical composition for use in the treatment of psoriasis comprising (a) 0.0001 to 30 weight percent of an anti-psoriatic agent selected from the group consisting of corticosteroids, calcipotriol, retinoids, tar, and mixtures thereof and (b) 15 to 97 weight percent isopropyl myristate, said component (a) being present in an effective anti-psoriatic weight percent, said pharmaceutical composition being a liquid and being in a form suitable for topical administration to a human.
A method of treating psoriasis comprising topically administering to a human having psoriasis a pharmaceutical composition comprising (a) 0.0001 to 30 weight percent of an anti-psoriatic agent selected from the group consisting of corticosteroids, calcipotriol, retinoids, tar, and mixtures thereof and (b) 15 to 97 weight percent isopropyl myristate, said component (a) being present in an effective anti-psoriatic weight percent, said pharmaceutical composition being a liquid and being in a form suitable for topical administration to a human.
Dependencies are inferred from the claim text.